目的:与COVID-19相关的儿童多系统炎症综合征(MIS-C)是一种罕见且严重的疾病。本研究旨在回顾临床表现,实验室参数,结果,以及叙利亚一家儿科医院的MIS-C病例管理。
方法:这项回顾性观察性研究旨在调查2020年5月至2021年10月之间的MIS-C。数据收集涉及从病历中提取信息,根据世界卫生组织(WHO)确定的病例定义确定患者。各种实验室调查,诊断评估,临床表现,并进行治疗以评估患者。使用MicrosoftExcel进行描述性统计分析。
结果:共报告COVID-19感染232例。在这些案例中,25(10.77%)被鉴定为MIS-C。患者的中位年龄为5.5岁,大多数是男性患者(72%)。患者出现发热(100%),双侧结膜炎(88%),皮疹(84%),胃肠道症状(76%),和心功能不全(72%)。其他值得注意的发现包括口腔变化(64%),水肿(36%),颈淋巴结肿大(36%),和神经系统表现(28%)。呼吸道症状并不常见(16%)。所有患者都康复了,没有死亡记录。
结论:本研究中大多数患者中SARS-CoV-2IgG阳性的主要存在支持MIS-C的感染后性质。儿科COVID-19和MIS-C患者的呼吸道症状较少。早期支持性护理在管理中至关重要,尽管需要更多的研究来建立明确的指南.需要更大的研究来克服这项研究的局限性,并增强我们对小儿COVID-19患者MIS-C的理解。
OBJECTIVE: Multisystem Inflammatory Syndrome in Children (MIS-C) associated with COVID-19 is a rare and serious medical condition. This study aims to review the clinical presentation, laboratory parameters, outcomes, and management of MIS-C cases in a pediatric hospital in Syria.
METHODS: This retrospective observational study aimed to investigate MIS-C between May 2020 and October 2021. Data collection involved extracting information from medical records, and patients were identified based on the case definition established by the World Health Organization (WHO). Various laboratory investigations, diagnostic evaluations, clinical presentations, and treatments were performed to assess patients. Descriptive statistical analysis was conducted using Microsoft Excel.
RESULTS: A total of 232 COVID-19 cases were reported with COVID-19 Infection. Among these cases, 25 (10.77%) were identified as MIS-C. The median age of the patients was 5.5 years, with the majority being male patients (72%). Patients experienced fever (100%), bilateral conjunctivitis (88%), rash (84%), gastrointestinal symptoms (76%), and cardiac dysfunction (72%). Other notable findings included oral cavity changes (64%), edema (36%), cervical lymphadenopathy (36%), and neurological manifestations (28%). Respiratory symptoms were uncommon (16%). All patients recovered, with no recorded deaths.
CONCLUSIONS: The predominant presence of positive SARS-CoV-2 IgG in the majority of patients in this study supports the post-infectious nature of MIS-C. Respiratory symptoms were less prevalent in both pediatric COVID-19 and MIS-C patients. Early supportive care is crucial in management, although additional research is needed to establish definitive guidelines. Larger studies are necessary to overcome the limitations of this study and to enhance our understanding of MIS-C in pediatric COVID-19 patients.